Showing 8471-8480 of 8876 results for "".
- Alphaeon to Acquire Clarion Medical Technologieshttps://practicaldermatology.com/news/20140909-alphaeon_to_acquire_clarion_medical_technologies/2459125/Alphaeon Corporation, a subsidiary of Strathspey Crown Holdings LLC, and Clarion Medical Technologies Inc. entered into a definitive agreement for Alphaeon to acquire all of the outstanding shares and assets of Clarion, a provider of medical and aesthetic equipment and consumabl
- The American Society of Laser Medicine & Surgery will Host Two Laser Aesthetics Courses in Fall 2014https://practicaldermatology.com/news/20140904-the_american_society_of_laser_medicine__surgery_will_host_two_laser_aesthetics_courses_in_fall_2014/2459128/In response to the success of its West Coast course, held annually at the Beckman Laser Institute in Irvine, CA, the American Society of Laser Medicine & Surgery (ASLMS) is initiating an East Coast Laser Aesthetics Course. The courses are designed for anyone who desires to have a deeper u
- FDA Approves Keytruda for Advanced Melanomahttps://practicaldermatology.com/news/20140904-fda_approves_keytruda_for_advanced_melanoma/2459129/The FDA granted accelerated approval to Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.Keytruda is the first approved drug that blocks a cellular pathway known as PD-1, which restricts the
- Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agencyhttps://practicaldermatology.com/news/20140904-amgen_submits_marketing_authorization_application_for_talimogene_laherparepvec_to_the_european_medicines_agency/2459130/Amgen recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. Talimogen
- Advanced Dermatology and Cosmetic Surgery (ADCS Clinics) Announces the Acquisition of Fort Collins Skin Clinichttps://practicaldermatology.com/news/20140903-advanced_dermatology_and_cosmetic_surgery_adcs_clinics_announces_the_acquisition_of_fort_collins_skin_clinic/2459132/ADCS Clinics (“ADCS”) announced it has completed the acquisition of Fort Collins Skin Clinic in Fort Collins, Colorado; a dermatology practice owned by Dr. Brad Baack and Dr. Andy Kalajian (both Board Certified Dermatologist and fellowship trained Mohs Micrographic Surgeons). Baack and Kalajian, wit
- Solace International Issues Recall of Dermatend Original and Dermatend Ultrahttps://practicaldermatology.com/news/20140902-solace_international_issues_recall_of_dermatend_original_and_dermatend_ultra/2459134/Solace International, Inc. is voluntarily recalling all lots of Dermatend Original and Dermatend Ultra in all sizes and dosage form to the distributor/wholesaler level. A mole should be removed under the supervision of a dermatologist. Dermatend is not FDA approved, thus has not
- Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase III Psoriasis Studieshttps://practicaldermatology.com/news/20140822-lillys_ixekizumab_superior_to_etanercept_and_placebo_in_phase_iii_psoriasis_studies/2459137/Eli Lilly and Company's ixekizumab was found to be statistically superior to etanercept and placebo on all skin clearance measures in pivotal, Phase III UNCOVER studies in moderate-to-severe plaque psoriasis. "These data are important for people suffer
- FDA Warns of Adverse Events Associated with Unapproved Use of Expression Injectable as a Dermal Fillerhttps://practicaldermatology.com/news/20140806-fda_warns_of_adverse_events_associated_with_unapproved_use_of_expression_injectable_as_a_dermal_filler/2459150/The FDA reported that it has become aware of adverse events associated with the unapproved use of the Expression product, hyaluronic acid that is packaged in a syringe, as a dermal filler. Events have included swelling, tenderness, firmness, lumps, bu
- Envy Medical and Libbs Farmaceutical Plan Strategic Marketing, Sales and Distribution Agreement For Brazilhttps://practicaldermatology.com/news/20140723-envy_medical_and_libbs_farmaceutical_plan_strategic_marketing_sales_and_distribution_agreement_for_brazil/2459159/Envy Medical and Libbs Farmaceutical made an agreement to manufacture, market and sell Envy's proprietary Lumixyl® Brightening Creme throughout the country of Brazil. This represents significant agreement with Libbs, a leader in the sales and supply of pharmaceutical products, it also rep
- Study: Dermatologists Preferred for Skin Cancer Evaluation and Treatmenthttps://practicaldermatology.com/news/20140722-study_dermatologists_preferred_for_skin_cancer_evaluation_and_treatment/2459161/Dermatologists are overwhelmingly the preferred health care provider for evaluating and treating skin cancer, according to a study published in the June issue of Dermatologic Surgery. In an online survey, respondents were asked their choice for evaluating a worrisome lesion on the face and for remov